
The Washington Post @washingtonpost
An experimental Alzheimer’s drug designed to slow cognitive decline failed to meet the goals of two closely watched clinical trials, a discouraging development that underscores the challenges of developing treatments for the memory-robbing disease. https://t.co/O1UYqIW9vW — PolitiTweet.org